Evidence map›Paper›PMID 40732313›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

Hsp90

Shiying Jia, Neeraj Maurya, Brian S J Blagg, Xin Lu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shiying JiaDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.ORCID 0009-0008-9890-5962
Neeraj MauryaDepartment of Chemistry and Biochemistry, Warren Center for Drug Discovery, University of Notre Dame, Notre Dame, IN 46556, USA.ORCID 0009-0007-6455-399X
Brian S J BlaggDepartment of Chemistry and Biochemistry, Warren Center for Drug Discovery, University of Notre Dame, Notre Dame, IN 46556, USA.ORCID 0000-0002-6200-3480
Xin LuDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.ORCID 0000-0002-0284-6478

Funding

Converting Cold to Hot Tumor Microenvironment in Prostate Cancer by Targeting Chromatin EffectorR01CA248033 · NCI · UNIVERSITY OF NOTRE DAME · PI LU, XIN · 2020 to 2024
$1.8M
Immunosuppression and Metabolic Rewiring in Tumor-infiltrating NeutrophilsR01CA280097 · NCI · UNIVERSITY OF NOTRE DAME · PI Xin Lu · 2023 to 2026
$1.4M
Developing isoform-selective Hsp90 inhibitors for monotherapy and enhanced immunotherapy against lethal prostate cancerR01CA297220 · NCI · UNIVERSITY OF NOTRE DAME · PI Brian S J Blagg, Xin Lu · 2025 to 2026
$1.1M
Boler Family Foundation n/aDepartment of Defense HT94252310010Department of Defense HT94252310613Department of Defense W81XWH2010312NCI NIH HHS R01 CA248033NCI NIH HHS R01 CA280097NCI NIH HHS R01 CA297220NIH HHS R01CA248033NIH HHS R01CA280097
6 · The paper itself

Abstract

The 90 kDa heat shock proteins (Hsp90) are molecular chaperones that regulate the stability and maturation of numerous client proteins implicated in the regulation of cancer hallmarks. Despite the potential of

Indexed as

cancer immunotherapydrug developmentGrp94heat shock responseHsp90 inhibitorsHsp90βisoform-selectivitytumor microenvironment

Identifiers

PMID40732313
PMCPMC12299041

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.